JPMorgan Chase & Co. Sells 502,997 Shares of Bruker Corporation $BRKR

JPMorgan Chase & Co. trimmed its position in Bruker Corporation (NASDAQ:BRKR) by 62.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,535 shares of the medical research company’s stock after selling 502,997 shares during the quarter. JPMorgan Chase & Co. owned 0.20% of Bruker worth $9,959,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BRKR. Nisa Investment Advisors LLC grew its position in Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares during the last quarter. Huntington National Bank increased its holdings in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares in the last quarter. Spire Wealth Management bought a new position in Bruker in the 2nd quarter worth approximately $32,000. True Wealth Design LLC lifted its holdings in Bruker by 16,716.7% during the 2nd quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock worth $42,000 after buying an additional 1,003 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its position in Bruker by 79.7% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after buying an additional 1,230 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $6,319,395.60. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 27.30% of the company’s stock.

Bruker Stock Performance

Shares of NASDAQ:BRKR opened at $36.68 on Friday. The firm’s 50 day simple moving average is $44.68 and its 200 day simple moving average is $40.96. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The company has a market capitalization of $5.58 billion, a price-to-earnings ratio of -244.53, a P/E/G ratio of 2.30 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The firm had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a $0.05 dividend. The ex-dividend date is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s dividend payout ratio is currently -133.33%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several research reports. Zacks Research raised Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. TD Cowen reduced their target price on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Rothschild & Co Redburn set a $60.00 price target on shares of Bruker in a research note on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. Finally, Bank of America lifted their target price on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $50.38.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.